$MRNA
Moderna Inc Stock $mrna

$mrna Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000168285224000027 Filed on May 02, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$241.0M	$167.0M
YoY Change	-29.94%	-91.03%
Cost Of Revenue	$115.0M	$96.00M
YoY Change	-84.27%	-87.88%
Gross Profit	$126.0M	$71.00M
YoY Change	-132.56%	-93.36%
Gross Profit Margin	52.28%	42.51%
Selling, General & Admin	$268.0M	$274.0M
YoY Change	-19.28%	-10.16%
% of Gross Profit	212.7%	385.92%
Research & Development	$1.221B	$1.063B
YoY Change	6.36%	-6.01%
% of Gross Profit	969.05%	1497.18%
Depreciation & Amortization	$40.00M	$35.00M
YoY Change	-56.52%	-55.13%
% of Gross Profit	31.75%	49.3%
Operating Expenses	$1.221B	$1.063B
YoY Change	-17.5%	-6.01%
Operating Profit	-$1.363B	-$1.266B
YoY Change	-27.0%	245.9%
Interest Expense	$82.00M	$99.00M
YoY Change	-27.43%	52.31%
% of Operating Profit
Other Income/Expense, Net	-$27.00M	-$19.00M
YoY Change	-640.0%	-60.42%
Pretax Income	-$1.279B	-$1.165B
YoY Change	-26.87%	281.97%
Income Tax	$0.00	$10.00M
% Of Pretax Income
Net Earnings	-$1.279B	-$1.175B
YoY Change	-7.32%	-1587.34%
Net Earnings / Revenue	-530.71%	-703.59%
Basic Earnings Per Share	-$3.33	-$3.07
Diluted Earnings Per Share	-$3.33	-$3.07
COMMON SHARES
Basic Shares Outstanding	383.2M shares	382.1M shares
Diluted Shares Outstanding	384.0M shares	382.0M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.488B	$8.523B
YoY Change	0.34%	-4.48%
Cash & Equivalents	$2.478B	$2.051B
Short-Term Investments	$6.010B	$6.472B
Other Short-Term Assets	$31.00M	$68.00M
YoY Change	-95.79%	6.25%
Inventory	$399.0M	$295.0M
Prepaid Expenses
Receivables	$163.0M	$137.0M
Other Receivables	$260.0M	$250.0M
Total Short-Term Assets	$9.661B	$9.600B
YoY Change	-8.85%	-20.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.971B	$2.760B
YoY Change	23.28%	29.27%
Goodwill	$52.00M	$52.00M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$31.00M	$53.00M
YoY Change	-99.49%	-36.14%
Other Assets	$641.0M	$650.0M
YoY Change	-76.86%	-44.16%
Total Long-Term Assets	$6.019B	$7.129B
YoY Change	-46.66%	-40.61%
TOTAL ASSETS
Total Short-Term Assets	$9.661B	$9.600B
Total Long-Term Assets	$6.019B	$7.129B
Total Assets	$15.68B	$16.73B
YoY Change	-28.35%	-30.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$279.0M	$183.0M
YoY Change	-10.0%	-52.96%
Accrued Expenses	$1.333B	$1.396B
YoY Change	-12.53%	-13.45%
Deferred Revenue	$702.0M	$559.0M
YoY Change	-32.5%	-54.14%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.363B	$2.380B
YoY Change	-24.34%	-31.98%
LONG-TERM LIABILITIES
Long-Term Debt	$576.0M	$575.0M
YoY Change	-31.67%	-30.81%
Other Long-Term Liabilities	$266.0M	$262.0M
YoY Change	-72.55%	60.74%
Total Long-Term Liabilities	$266.0M	$262.0M
YoY Change	-85.32%	60.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.363B	$2.380B
Total Long-Term Liabilities	$266.0M	$262.0M
Total Liabilities	$3.968B	$3.912B
YoY Change	-19.59%	-25.66%
SHAREHOLDERS EQUITY
Retained Earnings	$11.15B	$12.43B
YoY Change	-34.47%	-32.44%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.71B	$12.82B
YoY Change
Total Liabilities & Shareholders Equity	$15.68B	$16.73B
YoY Change	-28.35%	-30.66%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$1.279B	-$1.175B
YoY Change	-7.32%	-1587.34%
Depreciation, Depletion And Amortization	$40.00M	$35.00M
YoY Change	-56.52%	-55.13%
Cash From Operating Activities	-$1.274B	-$989.0M
YoY Change	39.23%	-19.27%
INVESTING ACTIVITIES
Capital Expenditures	$182.0M	$196.0M
YoY Change	-22.22%	73.45%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	$1.831B	$314.0M
YoY Change	-15.93%	-85.22%
Cash From Investing Activities	$1.649B	$118.0M
YoY Change	-15.17%	-94.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	34.00M	$14.00M
YoY Change	-105.09%	-102.58%
NET CHANGE
Cash From Operating Activities	-1.274B	-$989.0M
Cash From Investing Activities	1.649B	$118.0M
Cash From Financing Activities	34.00M	$14.00M
Net Change In Cash	409.0M	-$857.0M
YoY Change	13.3%	-451.23%
FREE CASH FLOW
Cash From Operating Activities	-$1.274B	-$989.0M
Capital Expenditures	$182.0M	$196.0M
Free Cash Flow	-$1.456B	-$1.185B
YoY Change	26.72%	-11.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001682852
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2024Q1	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	MRNA
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	383239726	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2051000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2907000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	6472000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	5697000000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	137000000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	892000000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	295000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	202000000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	645000000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	627000000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	9600000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	10325000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	3638000000	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	487000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	4677000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2063000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	1945000000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697000000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	713000000	usd
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	81000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	81000000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	650000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	685000000	usd
CY2024Q1	us-gaap	Assets Assets	16729000000	usd
CY2023Q4	us-gaap	Assets Assets	18426000000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	183000000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	520000000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1396000000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1798000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	559000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	568000000	usd
CY2024Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	52000000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	63000000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	190000000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	66000000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2380000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3015000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	58000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	83000000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	637000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	643000000	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	575000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	575000000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	262000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	256000000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	3912000000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4572000000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	383000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	383000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	382000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	382000000	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	371000000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-101000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-123000000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	12431000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	13606000000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	12817000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13854000000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16729000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18426000000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	96000000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	792000000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1063000000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1131000000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	274000000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	305000000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	1433000000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	2228000000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1266000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-366000000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	120000000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	109000000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-19000000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-48000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1165000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-305000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-384000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1175000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	79000000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.07
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.07
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	382000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	386000000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	382000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	405000000	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1175000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	79000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	20000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	79000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-2000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-16000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	22000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	95000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-8000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	8000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	22000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	103000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1153000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	182000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13854000000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15000000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	101000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	22000000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	12817000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	19123000000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9000000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	75000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	103000000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	526000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	79000000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	18863000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1175000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	79000000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	101000000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	75000000	usd
CY2024Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	36000000	usd
CY2023Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	78000000	usd
CY2024Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	27000000	usd
CY2023Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	17000000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	-13000000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	-18000000	usd
CY2024Q1	mrna	Deferred Income Tax Expense Benefit Net DeferredIncomeTaxExpenseBenefitNet	0	usd
CY2023Q1	mrna	Deferred Income Tax Expense Benefit Net DeferredIncomeTaxExpenseBenefitNet	-310000000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3000000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	4000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-755000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-272000000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3000000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	212000000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	93000000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-216000000	usd
CY2024Q1	mrna	Increase Decrease In Right Of Use Asset Operating Leases IncreaseDecreaseInRightOfUseAssetOperatingLeases	-16000000	usd
CY2023Q1	mrna	Increase Decrease In Right Of Use Asset Operating Leases IncreaseDecreaseInRightOfUseAssetOperatingLeases	-4000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-303000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-117000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-398000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-495000000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-33000000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-819000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-11000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	18000000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6000000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	4000000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	130000000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-15000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-989000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1225000000	usd
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2544000000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1085000000	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1573000000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1360000000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1285000000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1957000000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	196000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	113000000	usd
CY2024Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	85000000	usd
CY2024Q1	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0	usd
CY2023Q1	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	23000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	118000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2011000000	usd
CY2024Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	15000000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	9000000	usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	526000000	usd
CY2024Q1	mrna	Finance Lease Principal Payments Net Of Adjustments FinanceLeasePrincipalPaymentsNetOfAdjustments	1000000	usd
CY2023Q1	mrna	Finance Lease Principal Payments Net Of Adjustments FinanceLeasePrincipalPaymentsNetOfAdjustments	25000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-542000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-857000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	244000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2928000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3217000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2071000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3461000000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	91000000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	98000000	usd
CY2024Q1	mrna	Right Of Use Assets Obtained Through Finance Lease Modifications And Reassessments RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments	0	usd
CY2023Q1	mrna	Right Of Use Assets Obtained Through Finance Lease Modifications And Reassessments RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments	-60000000	usd
CY2024Q1	mrna	Number Of Development Candidates NumberOfDevelopmentCandidates	40	candidate
CY2024Q1	mrna	Number Of Development Programs NumberOfDevelopmentPrograms	47	developmentprogram
CY2024Q1	mrna	Number Of Development Programs Under Clinical Studies NumberOfDevelopmentProgramsUnderClinicalStudies	43	developmentprogram
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	22000000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2051000000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3441000000	usd
CY2024Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	17000000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3000000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	20000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2071000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3461000000	usd
CY2020Q2	mrna	Number Of Participants NumberOfParticipants	30000	participant
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	6536000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	6472000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	3696000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	3638000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	10232000000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	10110000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	5751000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	5697000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	4768000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	4677000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	10519000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	10374000000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	11000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	3669000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	114000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	5099000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	125000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	8768000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	4000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1369000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	147000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	6644000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	151000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	8013000000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	395	security
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	392	security
CY2024Q1	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	-13000000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	-18000000	usd
CY2024Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	42000000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	42000000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	215000000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	163000000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	60000000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	15000000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	20000000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	24000000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	295000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	202000000	usd
CY2024Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	145000000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	170000000	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	30000000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	148000000	usd
CY2024Q1	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	0	usd
CY2023Q1	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	66000000	usd
CY2024Q1	mrna	Legal Contingency Future Firm Purchase Commitments LegalContingencyFutureFirmPurchaseCommitments	24000000	usd
CY2023Q4	mrna	Legal Contingency Future Firm Purchase Commitments LegalContingencyFutureFirmPurchaseCommitments	79000000	usd
CY2024Q1	us-gaap	Inventory Gross InventoryGross	440000000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	372000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	2528000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	2378000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	465000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	433000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2063000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	1945000000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	35000000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	78000000	usd
CY2024Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	422000000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	1584000000	usd
CY2024Q1	mrna	Accounts Receivable Chargebacks Discounts And Fees AccountsReceivableChargebacksDiscountsAndFees	-285000000	usd
CY2023Q4	mrna	Accounts Receivable Chargebacks Discounts And Fees AccountsReceivableChargebacksDiscountsAndFees	-692000000	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	137000000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	892000000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	204000000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	182000000	usd
CY2024Q1	mrna	Other Prepaid Expense Materials And Supplies OtherPrepaidExpenseMaterialsAndSupplies	123000000	usd
CY2023Q4	mrna	Other Prepaid Expense Materials And Supplies OtherPrepaidExpenseMaterialsAndSupplies	168000000	usd
CY2024Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	93000000	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	19000000	usd
CY2024Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	62000000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	59000000	usd
CY2024Q1	mrna	Collaboration Receivable Current CollaborationReceivableCurrent	59000000	usd
CY2023Q4	mrna	Collaboration Receivable Current CollaborationReceivableCurrent	61000000	usd
CY2024Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	36000000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	50000000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	68000000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	88000000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	645000000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	627000000	usd
CY2024Q1	mrna	Downpayments And Prepayments Noncurrent DownpaymentsAndPrepaymentsNoncurrent	322000000	usd
CY2023Q4	mrna	Downpayments And Prepayments Noncurrent DownpaymentsAndPrepaymentsNoncurrent	342000000	usd
CY2024Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	145000000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	170000000	usd
CY2024Q1	us-gaap	Equity Method Investments EquityMethodInvestments	53000000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	66000000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	52000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	52000000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	43000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	44000000	usd
CY2024Q1	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	35000000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	11000000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	650000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	685000000	usd
CY2024Q1	us-gaap	Contract With Customer Refund Liability ContractWithCustomerRefundLiability	574000000	usd
CY2023Q4	us-gaap	Contract With Customer Refund Liability ContractWithCustomerRefundLiability	556000000	usd
CY2024Q1	mrna	Accrued Development Operation AccruedDevelopmentOperation	141000000	usd
CY2023Q4	mrna	Accrued Development Operation AccruedDevelopmentOperation	140000000	usd
CY2024Q1	mrna	Accrued Clinical Trials AccruedClinicalTrials	136000000	usd
CY2023Q4	mrna	Accrued Clinical Trials AccruedClinicalTrials	175000000	usd
CY2024Q1	mrna	Accrued Other External Goods And Services Current AccruedOtherExternalGoodsAndServicesCurrent	135000000	usd
CY2023Q4	mrna	Accrued Other External Goods And Services Current AccruedOtherExternalGoodsAndServicesCurrent	137000000	usd
CY2024Q1	mrna	Accrued Manufacturing AccruedManufacturing	112000000	usd
CY2023Q4	mrna	Accrued Manufacturing AccruedManufacturing	167000000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	95000000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	245000000	usd
CY2024Q1	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	95000000	usd
CY2023Q4	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	94000000	usd
CY2024Q1	mrna	Accrued Commercial AccruedCommercial	40000000	usd
CY2023Q4	mrna	Accrued Commercial AccruedCommercial	56000000	usd
CY2023Q4	mrna	Raw Materials Accounts Payable RawMaterialsAccountsPayable	27000000	usd
CY2024Q1	mrna	Raw Materials Accounts Payable RawMaterialsAccountsPayable	36000000	usd
CY2024Q1	mrna	Legal Contingency Future Firm Purchase Commitments LegalContingencyFutureFirmPurchaseCommitments	24000000	usd
CY2023Q4	mrna	Legal Contingency Future Firm Purchase Commitments LegalContingencyFutureFirmPurchaseCommitments	79000000	usd
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8000000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	122000000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1396000000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1798000000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	25000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	25000000	usd
CY2024Q1	mrna	Reimbursement Liability Current ReimbursementLiabilityCurrent	119000000	usd
CY2023Q4	mrna	Reimbursement Liability Current ReimbursementLiabilityCurrent	0	usd
CY2024Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	46000000	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	41000000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	190000000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	66000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	651000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress	17000000	usd
CY2024Q1	mrna	Contract With Customer Liability Deductions During Period ContractWithCustomerLiabilityDeductionsDuringPeriod	51000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	617000000	usd
CY2024Q1	mrna	Operating Lease Number Of Properties OperatingLeaseNumberOfProperties	2	campus
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697000000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	713000000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	433000000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	436000000	usd
CY2024Q1	mrna	Operating And Finance Lease Right Of Use Asset OperatingAndFinanceLeaseRightOfUseAsset	1130000000	usd
CY2023Q4	mrna	Operating And Finance Lease Right Of Use Asset OperatingAndFinanceLeaseRightOfUseAsset	1149000000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	25000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	25000000	usd
CY2024Q1	mrna	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	25000000	usd
CY2023Q4	mrna	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	25000000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	637000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	643000000	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	575000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	575000000	usd
CY2024Q1	mrna	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	1212000000	usd
CY2023Q4	mrna	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	1218000000	usd
CY2024Q1	mrna	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	1237000000	usd
CY2023Q4	mrna	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	1243000000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1175000000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	55000000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	14000000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	67000000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	22000000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	67000000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	22000000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	70000000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	23000000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	72000000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	23000000	usd
CY2024Q1	mrna	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	784000000	usd
CY2024Q1	mrna	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	1074000000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1115000000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1178000000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	453000000	usd
CY2024Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	603000000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	662000000	usd
CY2024Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	575000000	usd
CY2024Q1	mrna	Legal Contingency Future Firm Purchase Commitments LegalContingencyFutureFirmPurchaseCommitments	24000000	usd
CY2024Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	8000000	usd
CY2023Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	86000000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	101000000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75000000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	101000000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75000000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1200000000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2024Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1165000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-305000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-384000000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.009
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.259
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	79000000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	382000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	386000000	shares
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	19000000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	382000000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	405000000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.07
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.07
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35000000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5000000	shares

Files In Submission

Name	View Source	Status
0001682852-24-000027-index-headers.html	Edgar Link	pending
0001682852-24-000027-index.html	Edgar Link	pending
0001682852-24-000027.txt	Edgar Link	pending
0001682852-24-000027-xbrl.zip	Edgar Link	pending
exhibit3113312024.htm	Edgar Link	pending
exhibit3123312024.htm	Edgar Link	pending
exhibit3213312024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrna-20240331.htm	Edgar Link	pending
mrna-20240331.xsd	Edgar Link	pending
mrna-20240331_g1.jpg	Edgar Link	pending
mrna-20240331_g2.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mrna-20240331_cal.xml	Edgar Link	unprocessable
mrna-20240331_def.xml	Edgar Link	unprocessable
mrna-20240331_lab.xml	Edgar Link	unprocessable
mrna-20240331_pre.xml	Edgar Link	unprocessable
mrna-20240331_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRNA
Moderna Inc Stock $mrna

2024 Q2 Form 10-Q Financial Statement

#000168285224000027 Filed on May 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA Moderna Inc Stock $mrna

2024 Q2 Form 10-Q Financial Statement

#000168285224000027 Filed on May 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA
Moderna Inc Stock $mrna